Cancer Stem Cell News Volume 4.05 | Feb 5 2015

    Cancer Stem Cell News 4.05 February 11, 2015

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CSCN on Twitter

    Wnt/β-Catenin Small Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-Like Cells
    Scientists showed that the level of Wnt/β-catenin signaling in breast cancer stem cells (BCSC) is relatively higher than in bulk tumor cells, contributing to a relatively higher level of therapeutic resistance. Although CWP232228 inhibited the growth of both BCSC and bulk tumor cells by inhibiting β-catenin-mediated transcription, BCSC exhibited greater growth inhibition than bulk tumor cells. [Cancer Res] Abstract
    Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium

    PUBLICATIONS (Ranked by impact factor of the journal)
    Constitutive Activation of Myosin-Dependent Contractility Sensitizes Glioma Tumor-Initiating Cells to Mechanical Inputs and Reduces Tissue Invasion
    Researchers cultured primary human glioblastoma tumor-initiating cells on laminin-functionalized extracellular matrices (ECMs) spanning a range of stiffnesses. They found that these cells were largely insensitive to ECM stiffness cues, evading the inhibition of spreading, migration, and proliferation typically imposed by compliant ECMs. [Cancer Res] Abstract

    Targeting the hsp70 Gene Delays Mammary Tumor Initiation and Inhibits Tumor Cell Metastasis
    Investigators examined the role of heat-shock protein 70 (Hsp72) in mice, using animals in which the hsp70 gene was inactivated. They showed Hsp72 to be upregulated in a fraction of mammary cancer initiating cells within the mammary tumor virus tumor cell population. These cells were characterized by elevated surface levels of stem cell markers CD44 and Sca1 and by rapid metastasis. [Oncogene] Abstract

    CD38 Is a Putative Functional Marker for Side Population Cells in Human Nasopharyngeal Carcinoma Cell Lines
    Investigators identified side population (SP) cells, which are demonstrated rich in cancer stem cells (CSCs), in four nasopharyngeal carcinoma cell lines. SP cells displayed greater proliferation and invasion and expressed high levels of CSCs markers than non SP cells. [Mol Carcinog] Abstract

    Elimination of ALDH+ Breast Tumor Initiating Cells by Docosahexaenoic Acid and/or Gamma Tocotrienol through SHP-1 Inhibition of STAT3 Signaling
    Scientists investigated the ability of docosahexaenoic acid alone and in combination with gamma-tocotrienol to eliminate aldehyde dehydrogenase positive (ALDH+) cells and to inhibit mammosphere formation, biomarker and functional assay for tumor initiating cells. [Mol Carcinog] Abstract

    The Role of Polycomb Group Protein Bmi-1 and Notch4 in Breast Cancer Stem Cell Inhibition by Benzyl Isothiocyanate
    The authors provide insights into the mechanism by which benzyl isothiocyanate (BITC) inhibits breast cancer stem cells (bCSC). Inhibition of bCSC markers resulting from BITC exposure was significantly altered by Bmi-1 overexpression and knockdown. [Breast Cancer Res Treat] Abstract

    Poly r(C) Binding Protein-1 Is Central to Maintenance of Cancer Stem Cells in Prostate Cancer Cells
    Researchers investigated global proteomic changes induced in CD44+CD24 stem cells isolated from the prostate cancer cell lines, LNCaP and DU145, post prolonged TGF-β treatment in order to understand underlying mechanisms that promote stemness in prostate cancer cells. [Cell Physiol Biochem] Full Article

    Characterization and Propagation of Tumor Initiating Cells Derived from Colorectal Liver Metastases: Trials, Tribulations and a Cautionary Note
    Tissue was obtained from patients undergoing surgical resection for colorectal liver metastases, and processed into single cell suspension for assessment. Tumor initiating cells from liver metastases were characterized using combinations of EPCAM, Aldehyde dehydrogenase activity, CD133 and CD26. [PLoS One] Full Article

    miR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells
    Scientists explored the role of miR-494-3p and its molecular mechanism in human brain gliomas, malignant glioma cell lines, and cancer stem-like cells. Downregulated expression of miR-494-3p can inhibit the invasion and proliferation and promote apoptosis in glioma cells. [Cell Mol Neurobiol] Full Article

    Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells

    The Role of CD95 and CD95 Ligand in Cancer
    CD95 and CD95L were discovered to be critical survival factors for cancer cells, and were found to protect and promote cancer stem cells. The authors discuss five different ways in which inhibiting or eliminating CD95L, rather than augmenting, may be beneficial for cancer therapy alone or in combination with standard chemotherapy or immune therapy. [Cell Death Differ] Full Article

    Turning Hepatic Cancer Stem Cells Inside Out – A Deeper Understanding through Multiple Perspectives
    The authors discuss the recent findings on hepatic cancer stem cells (CSCs), with special emphasis on their putative origins, relationship with hepatitis viruses, regulatory signaling networks, tumor microenvironment, and how these factors control the stemness of hepatic CSCs. [Mol Cells] Abstract | Full Article

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer
    Oncolytics Biotech® Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of ovarian cancer. [Oncolytics Biotech® Inc.] Press Release

    FDA Grants Orphan Drug Designations to OncoMed’s Tarextumab for the Treatment of Pancreatic and Small Cell Lung Cancer
    OncoMed Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted orphan drug designation to tarextumab for the treatment of both pancreatic cancer and small cell lung cancer. [OncoMed Pharmaceuticals, Inc.] Press Release

    From our sponsor:
    View immunology lectures, protocols and other resources on the
    Human Immunology Portal.

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW 21st ISCT Annual Meeting
    May 27-30, 2015
    Las Vegas, United States

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW Research Technician II – Pediatric Cancer and Stem Cells (Massachusetts General Hospital)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Director – Vector Production (Sangamo BioSciences, Inc.)

    Senior Process Development Engineer (Sangamo BioSciences, Inc.)

    Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

    Junior Group Leaders – Cell Biology of Cancer and Genomic Instability (Foundation FIRC Institute of Molecular Oncology)

    Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health & Science University)

    Postdoctoral Positions – Cancer Bioengineering and Cancer Biology (University of Minnesota)

    Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

    Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

    Postdoctoral Positions – Functional Genomics of Stem Cells and Cancer (UT Southwestern Medical Center)

    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us